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Background: Recent increases in life expectancy may greatly expand future Alzheimer's Disease (AD) burdens.
China's demographic proﬁle, aging workforce and predicted increasing burden of AD-related caremake its econ-
omy vulnerable to AD impacts. Previous economic estimates of AD predominantly focus on health system bur-
dens and omit wider whole-economy effects, potentially underestimating the full economic beneﬁt of effective
treatment.
Methods: AD-related prevalence, morbidity and mortality for 2011–2050 were simulated and were, together
with associated caregiver time and costs, imposed on a dynamic Computable General Equilibrium model of the
Chinese economy. Both economic and non-economic outcomes were analyzed.
Findings: Simulated Chinese AD prevalence quadrupled during 2011–50 from 6–28 million. The cumulative
discounted value of eliminating AD equates to China's 2012 GDP (US$8 trillion), and the annual predicted real
value approaches US AD cost-of-illness (COI) estimates, exceeding US$1 trillion by 2050 (2011-prices). Lost
labor contributes 62% of macroeconomic impacts. Only 10% derives from informal care, challenging previous
COI-estimates of 56%.
Interpretation: Health and macroeconomic models predict an unfolding 2011–2050 Chinese AD epidemic with
serious macroeconomic consequences. Signiﬁcant investment in research and development (medical and non-
medical) is warranted and international researchers and national authorities should therefore target develop-
ment of effective AD treatment and prevention strategies.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
The last century witnessed dramatic global improvements in life ex-
pectancy and quality of life. However, since dementia primarily affects
those aged over 60, increased longevity has led to increased rates of de-
mentia and, more speciﬁcally, its most common form, Alzheimer's Dis-
ease (AD) (Prince et al., 2009). AD represents 42–81% of dementia
cases (Nussbaum and Ellis, 2003), and is characterized by progressive,
global deterioration of intellect, including memory, learning, orienta-
tion, language, comprehension and judgment. It affects the ability to
perform everyday activities (ADI, 2014), causes distress to patients
and their close contacts, creates extra demands on health systems, and
imposes a substantial burden of long-term care (Wimo et al., 1999).
There are currently no effective treatments or interventions to mitigate
AD progression, and the incidence rates for AD double every 5 years
from age 65 (Brookmeyer et al., 1998). The global burden of AD is there-
fore expected to accelerate in the face of reductions in mortality from
other conditions: from 26.6 million cases in 2006 to 106.8 million by
2050 (Brookmeyer et al., 2007). Some evidence suggests that incidence
rates for AD in the US and Europe may have declined in recent years
(Matthews et al., 2013;Qiu et al., 2013; Langa, 2015), possibly due to re-
duced exposure to minor life-style related AD risk factors such as obesi-
ty, diabetes and smoking (Langa, 2015; Satizabal et al., 2014). However,
dementia and, by implication, AD, has been highlighted as a particular
concern for China (Sousa et al., 2009), since life-style risk factors are cur-
rently increasing with growing income-levels and since the on-going
demographic transition combined with the demographic proﬁle
means that the primary risk factor for AD, aging, will drive future in-
creases in Chinese prevalence. Chinese life expectancy increased from
70.0 to 75.2 during 1993–2012 and population estimates (USCB,
2014) suggest that the proportion of the Chinese population aged 60
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and over, the ages at which onset of Alzheimer's Disease is most likely,
will increase from 12% in 2010 to 33% by 2050.
In addition to the burden on the population, it is hypothesized that
the considerable health and care burden of AD will impose a large eco-
nomic burden throughout affected economies. Previous economic stud-
ies estimate the 2009 worldwide cost of dementia to be US$421 billion
and attribute 10% of the global burden (US$41 billion) to China (ADI,
2009). Shanghai-speciﬁc per patient costs of AD were estimated to be
19,001RMB (US$2,384; 2006 prices) (Wang et al., 2008). However, indi-
rect (unpaid) caregiver costs (56%) drive the cost estimates and all pre-
vious estimates are formed by using a Cost-of-Illness (COI)-based
method to scale direct patient-speciﬁc and indirect caregiver and med-
ical costs by the number of cases. Existing estimates of AD therefore ig-
nore the wider spillover and interaction effects for the economy, in
general, and the extent to which these compound over time, and they
also commonly monetize caregiving time by non-workers. Over and
above the economic effects across sectors, the predicted scale of the fu-
ture Chinese AD health and economic burdens suggests that Chinese
labor markets may be affected. The combined interactions of China's
predicted economic development, increased proportion of elderly
workers, excess labor availability (Das and N'Diaye, 2013), and health
and caregiver burdens over time, will affect labor supply and wage
levels in awaywhich previously employedmethodologies cannot accu-
rately predict. These dynamic impacts, which are the fundamental units
by which health and care effects should be valued, can only be estimat-
ed using a macroeconomic multi-sector approach and yet no studies of
this nature have yet been conducted for AD or, more broadly, for
dementia.
Amulti-sectormacroeconomic simulationmodel is employed in this
study together with an epidemiological model of AD. The dual macro-
economic and disease simulations are employed to consistently esti-
mate the twin macroeconomic and health burdens of AD in China
from 2011 to 2050. The macroeconomic simulations focus on the accu-
rate estimation of dynamic labor supply and wage effects of AD health
and care burdens on working individuals whilst population-wide AD
health and care burdens are assessed in parallelwith themacroeconom-
ic effects and include the health and care impacts that fall outside the
labor force. The methodology employed to produce this holistic assess-
ment is outlined in the next section.
2. Methods
2.1. Study Design
The analysis presented in this paper employs a double-simulation
model framework consisting of an epidemiological model of AD pro-
gression and a macroeconomic Computable General Equilibrium
(CGE)model of the Chinese economy for 2011–2050. China is a compli-
cated country to undertake AD assessment given its rapid development,
aging population and changing labor market structures, but the CGE
model captures all relevant labor market structures as well as public
and private health budget shocks, including the burgeoning cohort of
60–70 year old workers, creating potential for dramatic increases in
the proportion of retired dependents with AD.
2.2. Alzheimer's Disease Model
A multistate probabilistic simulation model of AD progression
(Brookmeyer et al., 2007, 1998; Johnson et al., 2007; Colantuoni et al.,
2010) was used, based on Chinese population projections (USCB,
2014), age and gender-speciﬁc projections of Chinese mortality rates
(Banister and Hill, 2004) and age-speciﬁc exponentially growing pro-
jections of AD incidence rates from age 60 (Brookmeyer et al., 2007)
to forecast the number of Chinese individuals who contract AD. Whilst
incidence grows exponentially with age, age-speciﬁc incidence rates
are conservatively assumed to remain ﬁxed over time. Co-morbidities
of AD patients were not explicitly accounted for, but are implicitly cap-
tured in the mortality rates.
Two stages of AD were simulated. Stage 1 corresponds to mild or
moderate disease, and stage 2 corresponds to severe disease, as deﬁned
by the Clinical Dementia Rating (CDR) scale (Morris, 1993). Full discus-
sion of the AD progressionmodel is included in Appendix 1. The 11% an-
nual transition probability from stage 1 to stage 2 (Brookmeyer et al.,
2007) mirrors the observed transition from moderate AD to nursing
care (Neumann et al., 2001) and is consistent with the six year average
transition from detection to nursing care requirement (Stern et al.,
1997). Similar to previous AD model applications (Brookmeyer et al.,
2007), baseline simulations assumed no excess mortality for stage 1 pa-
tients but an annual 11% excess mortality rate for stage 2 patients. Pre-
viously established AD disability weights (Colantuoni et al., 2010;
Stouthard et al., 1997)were used to estimate Years Livedwith Disability
(YLD) effects.
2.3. Economic Model
The economic model used in this study was a macroeconomic Com-
putable General Equilibrium (CGE) model (Löfgren et al., 2002). CGE
models have been used successfully in health-related assessments of
pandemic inﬂuenza outbreaks (Smith et al., 2009), dietary change
(Lock et al., 2010), and environmental change (Jensen et al., 2013) and
a similar approach is applied here to assess the AD economic burden.
In particular, attention is given to both improved simulation of future
labor market wages at which economic burdens are assessed utilizing
literature-based predictions that excess unskilled labor supplies may
continue until 2025 (Das andN'Diaye, 2013) and separation of econom-
ic and non-economic impacts (monetizing only informal caregiver time
by employed caregivers). The analysis of economic impacts is enhanced
by using Net Present Value of GDP (NPV GDP) impact as the main mac-
roeconomic indicator of AD disease burden. This accounts for the time
value of money and so is the most relevant measure if the impacts are
to be used for long-term investment planning.
TheCGEmodelwas calibrated using a 2011 Social AccountingMatrix
(SAM) dataset for Chinawhichwas extracted from the GTAP 9 database
(GTAP, 2014). The static model was converted to a recursive-dynamic
model by introducing factor updating equations, expanded to account
for excess unskilled labor (until 2025) and ﬁtted to a counterfactual
growth path where growth rates decline linearly over time such that
Chinese GDP per capita converges to predicted UK-levels in 2050, in ac-
cordance with the recent 2011–2014 decline in Chinese growth rates.
The counterfactual solution for the model represents an annual series
of business-as-usual snapshots of the Chinese economy for 2011–
2050. AD burden scenarios were modelled as ‘health shocks’ to the
economy (described below), i.e. they were removed from the counter-
factual to result in an alternative set of snapshots, which was compared
with the counterfactual to estimate the relative economic disease bur-
den. More details on the CGE model and the SAM data set can be
found in Appendix 2.
2.4. Modelling AD Economic Burden from AD Health Forecasts
In order to measure the macroeconomic burden of AD, it is impor-
tant to accurately capture themain drivers. This analysis considered im-
pacts on the labor force and public health system costs to be the main
such drivers. Quantiﬁcation of ‘health shocks’ were based on the AD
model forecasts of prevalence and Disability-adjusted Life Years
(DALYs) as measured by the sum of Years Lived with Disability (YLD)
and Years of Life Lost (YLL) (see results below). The health forecasts
were used to derive labor market and health budget shocks based on
parameter values which are shown in Table 1. These parameter values
highlight the focus of our model shocks on the loss of productive labor
supply. Estimates suggest that 25.5% of informal caregivers lose time
from work and that their work-time loss averages 0.246 work-years
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(Mould-Quevedo et al., 2013) implying, that the total informal work-
time loss amounts to around 0.063work-years per AD patient-year. For-
mal care requirements are estimated to be 0.125-0.185 work-years per
AD patient-year in stages 1-2 based on cost estimates of formal caregiv-
ing (Wang et al., 2008).
In addition, Table 1 also presents upper and lower bounds on total
informal time-loss per AD patient-year, allowingmeasurement of infor-
mal caregiver time loss at different intervals (see caregiver indicators in
Table 2). For more details on the quantiﬁcation of ‘health shocks’, see
Appendix 3.
3. Results
3.1. AD Health Burden
The future Chinese AD prevalence and health burden is illustrated in
Fig. 1 for the period 2011–2050. Estimates of AD prevalence (Fig. 1a) in-
crease rapidly from 5.9 million to 27.7 million with just over 55% of in-
dividuals in stage 1 in 2050. The 2013 prevalence estimate of 6.4million
is in broad agreement with the recently published 2013 overall demen-
tia prevalence estimate of 10.5million for East Asia (Prince et al., 2013).
The AD health burden, measured by DALYs (Fig. 1b), increases from
6.2million to 22.4 million. The YLL share increases from 45% to 50% and
the share of stage 2 YLDs declines from 30% to 25% over the 40 year pe-
riod. Derived reductions in the effective labor force (Fig. 1c), which in-
clude direct health effects, and formal and informal caregiving, are
estimated to grow from 0.37% of the Chinese workforce in 2011 to
1.16% in 2050. Non-care costs as a share of government budgets
(Fig. 1d) decline over time due to conservative price-indexation ofmed-
ical unit costs. These ‘health shocks’ were imposed on the macroeco-
nomic model and results are presented in the next section.
3.2. AD Economic Burden
Table 2 presents the assessment of the AD economic burden, summa-
rizing cumulative health and caregiver indicators, derived from the above
AD health forecasts, and cumulative economic indicators in Net Present
Table 1
Parameter values for quantiﬁcation of health-to-economy impacts.
Disease Progression
Stage 1 Stage 2
1. Formal caregiving
–work-time (work-years per AD patient-year) 0.125 0.185
2. Informal caregiving
–Total time loss (years per AD patient-year)
–Lower bound (PADL) 0.200 0.200
–Upper bound (PADL + IADL) 0.463 0.463
–Work-time loss (work-years per AD patient-year per
caregiver) 0.246 0.246
–Informal caregivers with reduced work-time (%) 25.5% 25.5%
3. Non-care
–Medical costs (US$ per patient-year) 1,175 1,373
–Non-medical costs (US$ per patient-year) 212 64
Source: own calculations based on published sources (Wang et al., 2008; Mould-Quevedo
et al., 2013; Wimo et al., 2010). NB: PADL— personal activities of daily living; IADL— in-
strumental activities of daily living. Non-care medical costs consist of AD-related outpa-
tient costs, inpatient costs, medication costs and physical therapy costs, non-care non-
medical costs include transportation and special equipment . See appendices for additional
information.
Table 2
2011–2050 China AD disease burden (NPV; 8.0% p.a. discount rate).
Economic indicators Cumulative NPV GDP (2011–2050; US$ billion) % of NPV GDP (2011–2050) Share
AD economic burden 7,962 1.25% 100.0%
Decomposition 1
–Mortality 901 0.14% 11.3%
–Stage 1 3,585 0.56% 45.0%
–Stage 2 3,478 0.55% 43.7%
Decomposition 2
Direct patient-speciﬁc labor force reduction
–Mortality 901 0.14% 11.3%
–Morbidity 1,286 0.20% 16.2%
Indirect caregiver labor force reduction
–Formal caregiving 1,924 0.30% 24.2%
–Informal caregiving 798 0.13% 10.0%
Other indirect costs
–Medical costs 2,731 0.43% 34.3%
–Non-medical costs 319 0.05% 4.0%
Health indicators
AD prevalence Cumulative case-years (2011–50; millions) % of old-age population (age N 60)
Total prevalence 575 4.30%
–Stage 1 323 2.42% 56.1%
–Stage 2 252 1.89% 43.9%
AD health burden
Cumulative life-years
(2011–50; millions)
% of old-age population
(age N 60)
Total (=ΔDALY) 531 3.98%
–ΔYLL 244 1.82% 45.9%
–ΔYLD 287 2.15% 54.1%
Morbidity (=ΔYLD)
–Stage 1 132 0.99% 46.1%
–Stage 2 155 1.16% 53.9%
Caregiver indicators
Informal caregiver time loss Cumulative life-years (2011–50; millions) % of cumulative life-years (all ages)
–PADL (lower bound) 57 0.11%
–PADL + IADL (upper bound) 133 0.24%
Caregiver work-time loss Cumulative work-years (2011–50; millions) % of cumulative work-years (all ages)
Total 63 0.22%
–Formal caregiving 45 0.16% 71.5%
–Informal caregiving 18 0.06% 28.5%
Source: own simulations. NB: PADL— Personal Activities of Daily Living, IADL- Instrumental Activities of Daily Living.
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Value (NPV) terms. At the extreme, the complete eliminationof ADwould
increase the NPV of China's Gross Domestic Product (GDP) by US$8.0 tril-
lion between 2011 and 2050. Since previous valuations of the economic
costs of AD use different methodologies and value the components of
the economic disease burdendifferently, there are nodirectly comparable
disease burden estimates. However, to set this ﬁgure in context, this cu-
mulative 40 year impact is comparable to current estimates of China's
GDP in 2012 (US$8.1 trillion) and sufﬁcient to fund one quarter of
China's public health budget over the coming 40 years (currently 5.0–
5.4% of GDP).
Decomposing the economic indicators in Table 2 illustrates the rela-
tive importance of the main drivers. Decomposition 1 indicates that
morbidity effects (88.7%) exceed mortality effects (11.3%), while de-
composition 2 indicates that morbidity impacts are primarily driven
by medical costs (34.3%) and formal caregiving (24.2%). From a labor
market perspective, theAD economic burden is driven relatively equally
by three main categories of drivers, including direct patient-speciﬁc
labor effects (28%), indirect caregiver labor effects (34%), and other indi-
rect (medical) costs (38%). Labor market effects account for 62% of the
overall economic burden. This illustrates the importance of accurate
wage simulations for AD economic burden assessments.
The cumulative health indicators in Table 2 are consistentwith the AD
health burden results previously estimated and illustrate the large future
AD burden for Chinese citizens. Over the coming 40 years 4.3% of the Chi-
nese population aged over 60 are expected to develop AD, resulting in a
4.0% loss of DALYs attributable to AD. Labor effects from informal care-
givers account for only 10% of the overall economic burden, but, with
manymore suffering the burden of care and distress, non-economic care-
giver time loss among (older) caregivers is 3 to 7 fold (lower to upper
bound) larger than the labor market time loss to the economy. Non-
economic AD health burden indicators, including patient-speciﬁc func-
tional loss and non-economic caregiver time loss, represent important
complements to economic indicators from which decision makers can
assess human welfare implications of AD interventions and make invest-
ment decisions.
Accounting for population changes (Table 3) suggests that the eco-
nomic disease burden amounts to US$253 per capita per year. This sug-
gests that the economic burden of ADwill reduce the lifetime income of
all members of the Chinese population, regardless of age, by nearly one
percent, even after correcting for the time value ofmoney. The NPVGDP
impact per (living) patient case is estimated to be around US$45,300.
The dynamic trajectory of the AD economic burden is presented in
Fig. 2. For comparative and benchmark purposes, real GDP impacts
(2011 US$ prices) are presented in Fig. 2a–b, while NPV GDP impacts
are presented in Fig. 2c–d. The economic burden, assessed by real GDP im-
pact, grows exponentially from US$15 billion (2011) to US$1.07 trillion
(2050).Whilemethodologies differ, our 2050macroeconomic simulation
estimate is comparable in size to the COI-based 2050 prediction for the
United States AD economic burden, of US$1.10 trillion (2015-prices)
(AA, 2015), indicating that China may converge with the US over the
Fig. 1. Chinese AD disease-burden shocks.
Table 3
2011–2050 China AD economic burden per capita and per patient case-year (NPV; 8.0%
p.a. discount rate).
Avg. annual ΔNPV GDP per capita
ΔNPV GDP per patient
case-year
US$ (2011
NPV-values)
% of annual NPV GDP
per capita
US$ (2011
NPV-values)
% of
total
Total 253.4 0.89% 45,328
Decomposition 1
–Mortality −59.6 −0.21% 5,121 11.3%
–Stage 1 159.5 0.56% 20,416 45.0%
–Stage 2 154.7 0.55% 19,801 43.7%
Source: own simulations.
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coming 40 years both in terms of economic (wage) conditions and AD
health burdens.
The NPVGDPdynamic trajectories (Fig. 2c–d) of future AD economic
burdens also grow exponentially. By 2050 the economic burden on the
Chinese economy (US$559 billion) will be more than 37 times that of
2011 (US$15 billion). In addition, the decompositions of NPV GDP im-
pacts illustrate the jump in economic disease burden in 2025 (when un-
skilled labor is no longer in excess supply), the equal long-term
economic burden shares of stage 1 and 2morbidity effects (decomposi-
tion 1), and also the increases inmortality share (from1% in 2011 to 11%
in 2050) and direct morbidity share (from 2% in 2011 to 16% in 2050),
and the concomitant drop in medical burden share (from 63% in 2011
to 30% in 2050) (decomposition 2). The transition in burden shares re-
ﬂects both the increasing importance of health and caregiving needs
on the Chinese labor market and the decliningmedical expenses attrib-
utable to the conservative price-indexation of medical unit costs. If
medical unit costs were to increase more rapidly over time, both the
medical cost share and the overall economic disease burden, could in-
crease considerably. Overall, the rapid and accelerating expansion of
the AD economic burden reﬂects the importance of China's future de-
mographic transition and development growth path over the coming
40 years. More detailed analysis of the dynamic effects is given in Ap-
pendix 4.
3.3. Sensitivity Analyses
Sensitivity analyses were performed on AD health model assump-
tions, formal and informal care ratios andmacroeconomicmodel assump-
tions, and all assessments were made with reference to their cumulative
NPV GDP impact. Variation in AD health model assumptions followed
previous sensitivity analyses (Brookmeyer et al., 2007). Resultswere gen-
erally robust, but reducedAD incidence rates led to proportional NPVGDP
burden reductions. Reductions in the ratio of formal to informal care
(below current Shanghai levels) revealed that even extreme reductions
only reduce disease burdens by less than 5%. Results were also generally
robust to variation inmacroeconomicmodel assumptions, but reductions
in upperworking age (baseline: 79) reduced the NPVGDP burden by 10–
24%, while reductions in the conservative discount rate (baseline: 8.0%
p.a.) increased the NPV GDP burden by 31–129%. Our sensitivity analyses
(relating to changes in stage transition, more rapid mortality following
disease onset, and reduced incidence rates) suggest that beneﬁcial chang-
es in life-style related risk factors, similar to observed patterns in current
European and US cohorts, could ease the disease burden towards the end
of our time horizon, but any such changes are likely to have only small
(proportional) impacts on economic outcomes, and prolonged continua-
tion of current adverse Chinese trends couldworsen economic outcomes.
Details of the sensitivity analyses are presented in Appendix 5.
4. Discussion
The use of dual simulations in this study enables a comprehensive
assessment of the twin AD health and macroeconomic disease burdens
in China. The method combines health and macroeconomic modelling,
and thereby allows for consistent assessment of the twin burdens,
which are predicted to grow rapidly over the next 40 years. The models
predict an oncoming AD epidemic in China where the health burden,
measured by DALYs will more than quadruple over the coming
40 years, tripling the reductions in the effective labor supply attribut-
able to AD-related health and care effects and imposing large losses on
the macroeconomy. Despite conservative assumptions, including an
8% discount rate, the accelerating AD economic burden is predicted to
equate to China's total GDP for 2012 (around US$8.0 trillion). Over the
next 40 years, the increasing generations of older Chinese citizens will
impose an accelerating burden of AD care whilst increasing numbers
of working-age AD cases draw an ever-growing number of individuals
from their work, adding to the economic disease burden. As a result,
the annual real GDP impact is also predicted to grow at an accelerating
pace reaching US$1.07 trillion in 2050 (2011-prices) and approaching
Fig. 2. Chinese AD disease-burden dynamic real and NPV GDP effects.
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COI-based US predictions (2050: US$1.10 trillion (2015-prices)) (AA,
2015).
Overall, the results suggest that the cumulative AD economic burden
for China can be attributed equally to direct patient-speciﬁc labor effects,
indirect caregiver labor effects, and indirect non-labor (medical) costs.
Since 62% of the cumulative burden is attributable to direct and indirect
losses of productive labor, which could be used for other purposes, esti-
mates of the future economic impact of AD are critically dependent on ac-
curate estimation of future wages. This result highlights the strength of
the CGE approach. In contrast to existing COI-based studies, which use
simple wage projections, CGE models capture dynamic wage and labor
supply impacts and spillover effects across sectors. In this study, themac-
roeconomic CGE model determines wages from literature-based esti-
mates of the future development growth path, the future labor market
structure of China, and future AD health forecasts for China. This ensures
a robust assessment of future Chinese wages and results in accurate esti-
mates of labor supply impacts attributable to AD. In order to focus on
monetary outcomes, our assessment of productive labor supply only
monetizes informal caregiver time by employed caregivers, and thereby
excludes valuation of non-productive leisure or household work time
(which is more appropriately captured by non-economic caregiver indi-
cators). In order to test the robustness of the results to variations in
both macroeconomic and health assumptions, sensitivity analyses were
carried out. The sensitivity analyses revealed that the economic disease
burden is not very sensitive to the macroeconomic model assumptions
about the future development path and future labor market structure.
With the exception of halving incidence, which yielded a proportional
48.7% reduction in disease burden estimates, the results were also fairly
insensitive to changes in disease model parameters.
The quantiﬁcation of labor supply impacts in themacroeconomic CGE
model is also distinct from the previous COI-based Shanghai-speciﬁc as-
sessment which attributed 56% of costs per AD patient to informal care-
giving (Wang et al., 2008). In contrast, since the approach employed in
the CGE model only monetizes caregiving when it affects labor market
participation, the CGE results suggest that just over 10% of the AD eco-
nomic burden stems from labor lost due to informal caregiving. In order
to not lose sight of the caregiver burden, the AD economic burden indica-
torswere complementedwith additional non-economic caregiver indica-
tors on informal caregiver time use, and they show a 3–7 fold larger non-
economic time burden on (older) caregivers compared to (working-age)
labor-market time losses. While it is tempting to monetize unpaid care-
giver time use to avoid complexity, it is critical to keep the economic
andnon-economic assessments separate, so policymakers can be fully in-
formed about the multi-dimensionality of both monetary and other
human welfare impacts.
Categorization of AD in the epidemiological simulations differs from
some previous studies for China and the US (Wang et al., 2008; AA,
2015) which employed a three-state (mild, moderate, severe) categori-
zation. The current two-state speciﬁcation of AD (stage 1 and stage
2) encapsulates mild and moderate AD stages of previous studies as a
single state (stage 1). In order to ensure conservative cost estimation,
cost estimates from the literature for ‘mild’ AD were applied to stage 1
AD cases.
The holistic assessment of the health, caregiver, andmacroeconomic
burdens of AD in China should be of interest to both clinicians and policy
makers, since it highlights both the increasing burden of AD to which
health professionals and caregivers will be required to respond in the
future, and the economic burden that could be avoided by successful
policy-backed research and development of effective (medical and
non-medical) interventions. Whilst the absence of similar macroeco-
nomic analyses prevents like-for-like comparison with other disease
burdens, the conservative approach employed, combined with the ro-
bustness of results under sensitivity analysis invites trust in the magni-
tude of the estimates presented. One question which has not been
addressed in this study is the extent to which the effective treatment
of co-morbid conditions will affect the burden of AD but this question
hinges upon the causal link between co-morbid conditions and AD
which has still to be established (Poblador-Plou et al., 2014).
5. Conclusion
The combined health and macroeconomic assessment approach has
important advantages over existing COI-based methods. Future AD
health and economic burdens in China are signiﬁcant, but the burden
of AD impacts are clearly not limited to China, and further health and
macroeconomic assessments of both AD disease burdens, and preventa-
tive and curative therapies, are required to shed further light on our re-
sults and to compare them with nations at other development levels,
nations at other stages of demographic transition, and nations with
other labor market structures. Research into combatting other chronic
conditions should also be pursued and compared to AD assessments
by using similar multi-dimensional health and macroeconomic
methods. Nonetheless, the rapidly growing twin Chinese AD health
and economic burdens suggest that investment in accelerated research
programs for development of AD treatment and prevention interven-
tions could bring large and accelerating commercial and society-wide
human welfare gains over the medium to long term.
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